BR0315155A - Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina - Google Patents

Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina

Info

Publication number
BR0315155A
BR0315155A BR0315155-7A BR0315155A BR0315155A BR 0315155 A BR0315155 A BR 0315155A BR 0315155 A BR0315155 A BR 0315155A BR 0315155 A BR0315155 A BR 0315155A
Authority
BR
Brazil
Prior art keywords
cytokine
inhibiting
binding
activity
mutein
Prior art date
Application number
BR0315155-7A
Other languages
English (en)
Inventor
Charles A Dinarello
Soo-Hyun Kim
Philip Bufler
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of BR0315155A publication Critical patent/BR0315155A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)

Abstract

"USO DE CITOCINA CAPAZ DE LIGAR IL-18BP E DE INIBIR A ATIVIDADE DE UMA SEGUNDA CITOCINA". A presente invenção refere-se ao Uso de uma citocina-1, preferivelmente da família IL-1, mais preferivelmente IL-1F7b, ou uma isoforma, muteína, proteína fundida, derivado funcional ou fragmento desses, capaz de ligar-se a IL-18BP ou a uma muteína, proteína fundida, derivado funcional ou fragmento desses e capaz de inibir um receptor de uma citocina-2, a citocina-2 sendo um elemento da família IL-1, preferivelmente IL-18, na fabricação de um medicamento para o tratamento ou prevenção de uma doença que é causada por indução do receptor de citocina-2.
BR0315155-7A 2002-10-08 2003-10-03 Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina BR0315155A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41682702P 2002-10-08 2002-10-08
PCT/US2003/031378 WO2004032837A2 (en) 2002-10-08 2003-10-03 The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine

Publications (1)

Publication Number Publication Date
BR0315155A true BR0315155A (pt) 2005-08-16

Family

ID=32093906

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315155-7A BR0315155A (pt) 2002-10-08 2003-10-03 Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina

Country Status (15)

Country Link
US (2) US7279155B2 (pt)
EP (1) EP1572291B1 (pt)
JP (1) JP4563813B2 (pt)
KR (1) KR101015682B1 (pt)
CN (1) CN1909926A (pt)
AU (1) AU2003299919B2 (pt)
BR (1) BR0315155A (pt)
CA (1) CA2500577C (pt)
EA (1) EA008667B1 (pt)
ES (1) ES2416510T3 (pt)
IL (1) IL167769A (pt)
MX (1) MXPA05003869A (pt)
NO (1) NO337024B1 (pt)
UA (1) UA86750C2 (pt)
WO (1) WO2004032837A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
AU2003299919B2 (en) * 2002-10-08 2009-08-06 Ares Trading S.A. The use of cytokine able to bind IL-18BP and of inhibiting the activity of a second cytokine
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AU2006208241B2 (en) * 2005-01-25 2011-08-04 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
EP2160475A4 (en) * 2007-05-22 2011-02-09 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR EVALUATING AND TREATING CROHN'S DISEASE AND ASSOCIATED DISORDERS
JP7274259B2 (ja) * 2015-03-05 2023-05-16 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体
EP3600429B1 (en) * 2017-03-20 2023-10-25 Bio-Techne Corporation Il-37 fusion protein and methods of making and using same
BR112020004389A2 (pt) * 2017-09-06 2020-09-08 Yale University composição, e, método para tratar ou prevenir uma doença ou distúrbio em um indivíduo em necessidade do mesmo.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
WO1991009955A1 (en) 1989-12-22 1991-07-11 Applied Research Systems Ars Holding N.V. Endogenous gene expression modification with regulatory element
DK0554381T3 (da) * 1990-10-25 1996-04-09 Genentech Inc Anvendelse af beskyttende midler mod reaktive oxygenforbindelser
DK0567566T4 (da) 1991-01-18 2007-10-22 Amgen Inc Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme
US5945310A (en) * 1997-05-19 1999-08-31 Smithkline Beecham Corporation DNA encoding members of the IL-1 family, IL-1 delta
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) * 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
NZ505880A (en) * 1998-01-23 2003-06-30 Immunex Corp IL-18 receptor polypeptides
US6342371B1 (en) * 1999-04-16 2002-01-29 Smithkline Beecham Corporation Interleukin-1 homologue, IL-1H4
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
EP1233977A1 (en) * 1999-12-01 2002-08-28 SmithKline Beecham Corporation Interleukin-1 homologue, mat il-1h4
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
AU2003299919B2 (en) * 2002-10-08 2009-08-06 Ares Trading S.A. The use of cytokine able to bind IL-18BP and of inhibiting the activity of a second cytokine

Also Published As

Publication number Publication date
EP1572291B1 (en) 2013-04-03
US20040120923A1 (en) 2004-06-24
CA2500577A1 (en) 2004-04-22
JP2006516953A (ja) 2006-07-13
CN1909926A (zh) 2007-02-07
CA2500577C (en) 2013-12-17
US7820156B2 (en) 2010-10-26
UA86750C2 (ru) 2009-05-25
NO20052203L (no) 2005-05-04
ES2416510T3 (es) 2013-08-01
EA008667B1 (ru) 2007-06-29
KR20050074470A (ko) 2005-07-18
NO337024B1 (no) 2016-01-04
NO20052203D0 (no) 2005-05-04
AU2003299919B2 (en) 2009-08-06
US20090074710A1 (en) 2009-03-19
WO2004032837A2 (en) 2004-04-22
MXPA05003869A (es) 2005-06-22
IL167769A (en) 2013-10-31
EP1572291A2 (en) 2005-09-14
WO2004032837A3 (en) 2006-04-13
EA200500617A1 (ru) 2006-08-25
EP1572291A4 (en) 2009-06-24
AU2003299919A1 (en) 2004-05-04
KR101015682B1 (ko) 2011-02-22
US7279155B2 (en) 2007-10-09
JP4563813B2 (ja) 2010-10-13

Similar Documents

Publication Publication Date Title
BRPI0313733A8 (pt) Uso da proteína n beta cinase
BRPI0409910A (pt) métodos para o tratamento de doenças relacionadas com interleucina-6
SV2003001107A (es) Imidazotriazinas ref.lea 35368
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
BR0312758A (pt) Derivados de 1-heterociclilalquil-3-sulfonilazaindol ou -azaindazol como ligantes da 5-hidroxitriptamina-6
BR0312759A (pt) Derivados de 1-heterociclilalquil-3-sulfonilindol ou -indazol como ligantes de 5-hidroxitriptamina-6
BR9810955A (pt) "4-5-diaril imidazóis 2-substituìdo"
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BR0209056A (pt) Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
BRPI0507877A (pt) derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
BRPI0510762A (pt) derivados de tetraidronaftiridina úteis como ligantes do receptor de histamina h3
BRPI0410129B8 (pt) anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica
GT200200188A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
BR0215222A (pt) Derivados de indolilalquilamina como ligantes de 5-hidroxitriptamina-6
BR0312456A (pt) Anticorpo alterado ou fragmento funcional do mesmo, polinucleotìdeo, sequência de polinucleotìdeo, composição farmacêutica, métodos de tratamento ou profilaxia de derrame e outras doenças/distúrbios neurológicos em um ser humano, de inibição da neurodegeneração e/ou promoção da recuperação funcional e de promoção do desenvolvimento axonial, e, uso de um anticorpo anti-mag
UY27392A1 (es) Derivados del ácido indan acetico y su uso como agentes farmacéuticos, intermediarios, y método de preparación
NO20052203D0 (no) Anvendelse av cytokin som kan binde IL-18BP og inhibere aktiviteten til et andre cytokin
CY1110866T1 (el) Μακρολιδια με αντι-φλεγμονωδη δραστηριοτητα
BR0209047A (pt) Derivados de heterociclilalcóxi-, -alquiltio- e -alquilaminobenzazol como ligantes de 5-hidroxitriptamina-6
Rainey‐Smith et al. Tumour necrosis factor alpha induces rapid reduction in AMPA receptor‐mediated calcium entry in motor neurones by increasing cell surface expression of the GluR2 subunit: relevance to neurodegeneration
BR0316261A (pt) Composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade caracterizada por renovação, ativação, ou renovação e ativação de leucócitos patogênicos e método de antagonização de um receptor de quimioquinas c-c 1 em um paciente

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2470 DE 08/05/2018.